GlassScriptPhysician profile
David R Allen
NPI 1295884021
$7,537.48
in general payments reported to CMS, 2019-2025
67 companies · $1,325 in 2025
The $1,325 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $786 · 2021: $1,107 · 2022: $1,055 · 2023: $1,084 · 2024: $1,516 · 2025: $1,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,925.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,239.43 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $1,174.28 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $510.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $481.21 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $390.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $265.24 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $250.94 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $243.84 | 2022-2024 | Rexulti, Abilify Maintena |
| Antares Pharma, INC. | $230.18 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $214.76 | 2022-2025 | |
| Pfizer INC. | $200.92 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.56 | 2020-2025 | Xifaxan |
| Abbott Laboratories | $113.49 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $106.29 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $93.10 | 2022-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.